S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)
NASDAQ:AVTX

Avalo Therapeutics - AVTX News Headlines

$5.36
-0.42 (-7.27%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.12
$5.66
50-Day Range
$3.50
$62.16
52-Week Range
$2.42
$38.88
Volume
52,638 shs
Average Volume
49,702 shs
Market Capitalization
$50.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
Get Avalo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.

AVTX Media Mentions By Week

AVTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AVTX
News Sentiment

0.95

0.63

Average
Medical
News Sentiment

AVTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AVTX Articles
This Week

16

1

AVTX Articles
Average Week



SourceHeadline
MarketBeat logoQ3 2022 EPS Estimates for Avalo Therapeutics, Inc. Lifted by Analyst (NASDAQ:AVTX)
americanbankingnews.com - August 12 at 3:24 AM
MarketBeat logoAvalo Therapeutics, Inc. (NASDAQ:AVTX) Forecasted to Post Q3 2022 Earnings of ($1.03) Per Share
americanbankingnews.com - August 12 at 2:47 AM
finance.yahoo.com logoAvalo Therapeutics Announces Board Changes
finance.yahoo.com - August 11 at 8:38 PM
finance.yahoo.com logoWall Street Analysts Predict a 230% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should Know
finance.yahoo.com - August 10 at 4:58 PM
MarketBeat logoAvalo Therapeutics, Inc. Forecasted to Earn Q1 2023 Earnings of ($0.95) Per Share (NASDAQ:AVTX)
americanbankingnews.com - August 9 at 6:52 AM
finance.yahoo.com logoAvalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
finance.yahoo.com - August 4 at 10:59 AM
finance.yahoo.com logoAvalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
finance.yahoo.com - August 4 at 10:59 AM
seekingalpha.com logoAvalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007
seekingalpha.com - August 2 at 8:47 PM
finance.yahoo.com logoAvalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
finance.yahoo.com - August 2 at 10:46 AM
MarketBeat logoAvalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Large Growth in Short Interest
americanbankingnews.com - August 2 at 3:52 AM
finance.yahoo.com logoAvalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
finance.yahoo.com - August 1 at 8:43 AM
finance.yahoo.com logoAvalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
finance.yahoo.com - August 1 at 8:43 AM
finance.yahoo.com logoAvalo Therapeutics Announces One-for-Twelve Reverse Stock Split
finance.yahoo.com - July 6 at 5:45 PM
finance.yahoo.com logoInvestors in Avalo Therapeutics (NASDAQ:AVTX) have unfortunately lost 90% over the last three years
finance.yahoo.com - June 20 at 5:15 PM
finance.yahoo.com logoAvalo to Present at the 2022 Jefferies Healthcare Conference
finance.yahoo.com - June 2 at 10:44 AM
seekingalpha.com logoAvalo begins dosing in mid-stage study of AVTX-002 for non-eosinophilic asthma
seekingalpha.com - May 18 at 5:32 PM
finance.yahoo.com logoAvalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)
finance.yahoo.com - May 18 at 8:56 AM
finance.yahoo.com logoAvalo to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - May 17 at 8:30 AM
nasdaq.com logoAvalo Therapeutics vs. Bitcoin: Price Relationship Crosses Threshold
nasdaq.com - May 16 at 5:29 PM
benzinga.com logoAvalo Therapeutics First Quarter 2022 Financial Results and Business Updates
benzinga.com - May 5 at 10:29 AM
finance.yahoo.com logoAvalo Therapeutics First Quarter 2022 Financial Results and Business Updates
finance.yahoo.com - May 5 at 10:29 AM
barrons.com logoAvalo Therapeutics Inc.
barrons.com - April 8 at 4:15 AM
finance.yahoo.com logoAvalo to Present at Oppenheimer's 32nd Annual Healthcare Conference
finance.yahoo.com - March 8 at 11:51 AM
benzinga.com logoRBC Capital Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $4
benzinga.com - March 3 at 3:27 PM
seekingalpha.com logoAvalo Therapeutics GAAP EPS of -$0.83 in-line, revenue of $5.4M misses by $0.68M
seekingalpha.com - March 2 at 8:35 AM
apnews.com logoAvalo Therapeutics Reports 2021 Financial Results and Provides Business Updates
apnews.com - March 2 at 8:35 AM
finance.yahoo.com logoAvalo Therapeutics Reports 2021 Financial Results and Provides Business Updates
finance.yahoo.com - March 2 at 8:35 AM
seekingalpha.com logoAvalo Therapeutics picks internal candidate for CEO and CFO role
seekingalpha.com - February 17 at 10:28 AM
finance.yahoo.com logoAvalo Therapeutics Announces Leadership Transition
finance.yahoo.com - February 17 at 10:28 AM
finance.yahoo.com logoAvalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference
finance.yahoo.com - February 7 at 6:50 PM
nasdaq.com logoAvalo Therapeutics, Inc. Common Stock (AVTX)
nasdaq.com - January 26 at 12:58 AM
seekingalpha.com logoNew commercial chief at Avalo Therapeutics
seekingalpha.com - January 11 at 9:27 AM
finance.yahoo.com logoAvalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer
finance.yahoo.com - January 10 at 11:26 PM
nasdaq.com logoAvalo Therapeutics Inc Shares Close the Day 31.3% Lower - Daily Wrap
nasdaq.com - January 7 at 10:43 AM
marketwatch.com logoAvalo Therapeutics Shares Drop 23% After Data for Crohn's, Melanoma Treatments
marketwatch.com - January 6 at 2:06 PM
seekingalpha.com logoAvalo Therapeutics discontinues multiple myeloma program; stock plunges 23%
seekingalpha.com - January 6 at 2:06 PM
finance.yahoo.com logoAvalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event
finance.yahoo.com - January 6 at 9:06 AM
finance.yahoo.com logoAvalo Therapeutics to Host Virtual Investor Day on January 6, 2022
finance.yahoo.com - December 16 at 9:46 AM
finance.yahoo.com logoAvalo Appoints Two New Independent Directors to Its Board
finance.yahoo.com - December 6 at 8:49 AM
finance.yahoo.com logoWhat Type Of Shareholders Make Up Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) Share Registry?
finance.yahoo.com - December 5 at 9:39 AM
nasdaq.com logoDo Options Traders Know Something About Avalo (AVTX) Stock We Don't?
nasdaq.com - November 17 at 2:31 PM
finance.yahoo.com logoAvalo to Present at Two Upcoming Conferences
finance.yahoo.com - November 11 at 9:12 AM
finance.yahoo.com logoAvalo Reports Third Quarter 2021 Financial Results and Provides Business Updates
finance.yahoo.com - November 9 at 8:17 PM
finance.yahoo.com logoAvalo Therapeutics, Inc. (AVTX)
finance.yahoo.com - November 7 at 12:24 AM
nasdaq.com logoAvalo Therapeutics (NASDAQ:AVTX) shareholders have endured a 47% loss from investing in the stock three years ago
nasdaq.com - November 5 at 9:38 AM
finance.yahoo.com logoAvalo to Present at the 2021 Cantor Virtual Global Healthcare Conference
finance.yahoo.com - September 20 at 7:58 AM
finance.yahoo.com logoAvalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
finance.yahoo.com - September 17 at 3:01 PM
reuters.com logoAVTX.OQ - Avalo Therapeutics Inc Profile | Reuters
reuters.com - September 17 at 8:39 AM
finance.yahoo.com logoAvalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
finance.yahoo.com - September 14 at 11:01 PM
finance.yahoo.com logoAvalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 14 at 6:01 PM
Get Avalo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:AVTX) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.